

Pharmacological Aspects, will be held May 4–8, 2002, in Grieghallen, Bergen, Norway. For further information, contact: Norwegian Biochemical Society, c/o Dr. Knut-Jan Andersen, University of Bergen, Institute of Medicine, Haukeland Hospital, N-5021 Bergen, Norway. Telephone: +47-55973054; Fax: +47-55975890; E-mail: kja@med.uib.no; Internet: <http://www.biokjemisk.com/kongress2002/>

The 19th Scientific Meeting of the International Society of Hypertension and the 12th European Meeting on Hypertension will be held June 23–27, 2002, in Prague, Czech Republic. For further information, contact: Congress Secretariat. Telephone: 004202 8400 1477 or 004202 8400 1444; Fax: 004202 8400 1448; E-mail: hypertension2002@guarant.cz; Web site: www.hypertension2002.cz. A satellite symposium on renal hypertension will be held Sunday, June 23, 2002, in Liberec, Czech Republic. For further information, contact: Prof. Vladimir Tesar, Division of Nephrology, 1st Department of Medicine, Charles University, U nemocnice 2, Prague 2, Czech Republic. Telephone/fax: 004202 24962696; E-mail: tesarv@beba.cesnet.cz

The Fifth International Congress on Mechanisms of Uremic Toxicity will be held September 13–16, 2002, at the University Church, Würzburg, Germany. The meeting will feature current information on uremia and the cardiovascular system. The deadline for abstract submission is April 22, 2002. The complete program listing is available at <http://www.uni.wuerzburg.de/nephrologie>. For further information, contact: Professor Christoph Wanner, Department of Medicine, Division of Nephrology, University of Würzburg, Josef-Schneider Str. 2, D-97080 Würzburg, Germany. Fax: +49 932 201 3502; E-mail: c.wanner@medizin.uni-wuerzburg.de

AWARDS AND GRANTS

The National Kidney Foundation (NKF) is inviting applications for its research grants and training awards. Fellowship candidates must apply by November 1, 2001, for funding effective July 1, 2002. Applications for Young Investigator Grants (\$50,000 per year for two years), Clinical Scientist Awards (\$50,000 per year for three years), and all other mechanisms for support must submit proposals by February 1, 2002, for funding that will be available on July 1, 2002. Applications will be available on the Web site beginning July 1, 2001. For further information, contact the National Kidney Foundation. Telephone: 1-800-889-9559; Web site: www.kidney.org

BOOKS RECEIVED (for December 2001 issue)

Immunologic Renal Diseases, Second Edition, edited by Eric G. Neilson and William G. Couser. Philadelphia: Lippincott Williams & Wilkins, 2001. ISBN: 0-7817-2773-1. This second edition of the highly regarded text

offers readers an up-to-date collaboration of the discipline of immune renal disease by the editors and the 105 listed contributors. The text is divided into four basic sections: process-related pathology; the immune response and renal injury; mediation of immune renal injury; and animal models of immunologic renal disease. Within those four sections, subsections range from induction of the nephritogenic immune response and the mechanisms of immune injury; humoral mediators of immune injury and cellular mediators of immune injury; and patient evaluation and general considerations, primary glomerular diseases, secondary glomerular diseases, and interstitial nephritis. The 1328-page text includes a total of 53 chapters, each of which includes illustrations, tables, and a listing of references. The text is also completely indexed. The price for this second edition is \$299.00.

ERRATUM

FURNESS PN, TAUB N, for the Convergence of European Renal Transplant Pathology Assessment Procedures (CERTPAP) Project: International variation in the interpretation of renal transplant biopsies: Report of the CERTPAP Project. *Kidney Int* 60:1998–2012, 2001

In the above-cited article, on page 1999, in the second column, in the second full paragraph, the third line from the end of the paragraph to the end of the paragraph should read as follows:

Participants were viewing significantly different section. An assessment of the impact of this effect was made, as discussed later in this article.

On page 2006, in the first column, in the first full paragraph, line 7, the cited *P* value should be corrected to read as follows:

$$(P = 0.03)$$

On page 2006, in the second column, under the heading **Correlation with clinical outcome**, in the paragraph entitled *Testing for acute rejection*, the last word in the 10th line should be corrected to read as follows:

the

On page 2007, the title of Table 4 should be corrected to read as follows:

Table 4. Evidence of improved inter-observer agreement over the course of the study

On page 2011, the title of the legend of Figure 6 should be corrected to read as follows:

Fig. 6. The problem of assessing area affected by a progressive process.

The authors and the Editor apologize for the errors.